A Two-Part, Sequential Design Study to Determine Debio 0932 Absolute Oral Bioavailability, Mass Balance Recovery, Metabolite Profiling and Structural Identification in 3 Cohorts of Healthy Male Subjects

Trial Profile

A Two-Part, Sequential Design Study to Determine Debio 0932 Absolute Oral Bioavailability, Mass Balance Recovery, Metabolite Profiling and Structural Identification in 3 Cohorts of Healthy Male Subjects

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2013

At a glance

  • Drugs CUDC 305 (Primary)
  • Indications Lymphoma; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 03 Dec 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database
    • 30 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top